Method: A three-year pilot cascade screening service wasundertakenat theLipidDisordersClinicatRoyalPerth Hospital.We assessed the effectiveness of cascade screening and treatment with cholesterol lowering medication. The number of non-fatal myocardial infarctions (MI) prevented as a result of treatment with statin was estimated using two methods. Results: 274 cases of FH were identified (1.13 relatives/index case); detection rates were higher with larger pedigrees. Participation and satisfaction rates were high; 88% of patients surveyed were highly satisfied with the program. Plasma LDL-cholesterol levels in statin naive patients fell by 42%andby a further 9% in those already on a statin. Preliminary estimates suggest that from22 andup to 111MIswereprevented for every 100 cases of FH treated with statin. Conclusion: Cascade screening is an effective method for identifying new cases of FH in the Australian setting. Treatment of FH patients with statin therapy leads to significant reductions in LDL-cholesterol and prevention of non-fatal MI. This reduction in coronary events is likely to generate cost savings. However, these savings need to be weighed against costs of screening and treatment, and this balance needs to be subjected to a detailed economic evaluation. doi:10.1016/j.hlc.2011.05.137 Conclusions: TNP-470 produces a robust reduction in tumour growth but is associated with a significant loss of bodyweight, which may limit its clinical application. High dose rHDL infusions had no effect on tumour mass in the murine LLC model. Further studies are needed in other tumour models. doi:10.1016/j.hlc.2011.05.138